E Fund Management Co. Ltd. Purchases Shares of 48,412 Ocugen, Inc. (NASDAQ:OCGN)

E Fund Management Co. Ltd. acquired a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 48,412 shares of the company’s stock, valued at approximately $75,000.

Other institutional investors also recently modified their holdings of the company. David J Yvars Group purchased a new position in Ocugen in the 1st quarter worth approximately $35,000. Baader Bank Aktiengesellschaft purchased a new position in Ocugen in the second quarter worth $35,000. Victory Capital Management Inc. bought a new position in Ocugen in the second quarter valued at $51,000. Headlands Technologies LLC bought a new stake in Ocugen during the first quarter worth about $66,000. Finally, Daiwa Securities Group Inc. purchased a new position in shares of Ocugen in the 2nd quarter worth about $67,000. 10.27% of the stock is currently owned by institutional investors.

Ocugen Price Performance

Shares of Ocugen stock opened at $1.14 on Friday. The business’s 50-day moving average price is $1.36 and its 200-day moving average price is $1.45. The firm has a market capitalization of $293.38 million, a PE ratio of -4.56 and a beta of 3.69. Ocugen, Inc. has a 12 month low of $0.35 and a 12 month high of $2.11. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.09.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The business had revenue of $1.14 million for the quarter. During the same quarter in the previous year, the business earned ($0.10) earnings per share. Sell-side analysts forecast that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Ocugen Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.